Phase i study of the infectivity, safety and immunogenicity of two recombinant, live-attenuated, bovine/human, parainfluenza virus type 3 (b/HPIV3) vector vaccines expressing the fusion glycoprotein…
Active Awarded Last action
- Contract number
- 75N93023F00002
- Awardee
-
The Johns Hopkins University UEI FTMTDMBR29C7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,628,715
Award facts
- Contract value 100% obligated
- $3,628,715.00 Current and potential, with all options
- Completion date 67% complete
- Current and potential, with all options
- Funding agency
- National Institute on Drug Abuse National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Baltimore, MD 21205, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,628,715 |
About this award
The National Institute on Drug Abuse issued a delivery order to The Johns Hopkins University on May 5, 2023, with a ceiling value of $3.6 million under cost-no-fee pricing for a Phase I study of recombinant, live-attenuated bovine/human parainfluenza virus type 3 vector vaccines expressing the fusion glycoprotein of human metapneumovirus, delivered by nasal spray.
Place of performance is Baltimore, MD. The order runs through June 30, 2028. No set-aside was used.
In FY2024, the order invoiced $264 thousand across 1.5 FTEs and 3,194 contractor hours, reflecting a blended government-paid hourly rate of $82.57. Subcontractors performed 88 percent of contractor hours, with two subcontractors engaged in the most recent reported fiscal year.
Description
Phase i study of the infectivity, safety and immunogenicity of two recombinant, live-attenuated, bovine/human, parainfluenza virus type 3 (b/HPIV3) vector vaccines expressing the fusion glycoprotein of human metapneumovirus, delivered by nasal spray
Quick answers
Who was awarded contract 75N93023F00002?
75N93023F00002 was awarded to The Johns Hopkins University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 5, 2023.
How much is contract 75N93023F00002 worth?
The government has obligated $3,628,715 on 75N93023F00002.
Which agency awarded contract 75N93023F00002?
National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded 75N93023F00002, with funding from National Institute on Drug Abuse (National Institutes of Health).
Is contract 75N93023F00002 an order under another contract?
Yes. 75N93023F00002 is a delivery order under 75N93019D00031, an indefinite delivery contract.
Was contract 75N93023F00002 competed?
The extent of competition for 75N93023F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award